Logo

SGMO

Sangamo Therapeutics, Inc.

SGMO

Sangamo Therapeutics, Inc. • NASDAQ
$0.46 ▼ -0.56% (-0.00)
Market Cap $155.29 M
52w High $2.84
52w Low $0.38
Dividend Yield 0%
P/E -1.03
Volume 2.81M
Outstanding Shares 336.49M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $581K ▼ $36.134M ▼ $-34.93M ▼ -6.012K% ▼ $-0.11 ▼ $-33.193M ▼
Q2-2025 $18.306M ▲ $36.161M ▲ $-19.986M ▲ -109.177% ▲ $-0.078 ▲ $-18.062M ▲
Q1-2025 $6.437M ▼ $36.065M ▲ $-30.597M ▼ -475.33% ▼ $-0.14 ▼ $-27.704M ▼
Q4-2024 $7.551M ▼ $33.541M ▼ $-23.396M ▼ -309.84% ▼ $-0.11 ▼ $-23.855M ▼
Q3-2024 $49.412M $38.781M $10.672M 21.598% $0.045 $12.758M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $30.528M ▼ $88.643M ▼ $82.4M ▲ $6.243M ▼
Q2-2025 $38.344M ▲ $97.558M ▲ $77.956M ▼ $19.602M ▲
Q1-2025 $25.18M ▼ $86.166M ▼ $81.26M ▲ $4.906M ▼
Q4-2024 $41.918M ▲ $101.635M ▼ $78.865M ▲ $22.77M ▼
Q3-2024 $39.201M $111.263M $72.129M $39.134M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-34.93M ▼ $-28.498M ▼ $-64K ▼ $19.204M ▼ $-7.816M ▼ $-28.562M ▼
Q2-2025 $-19.986M ▲ $-18.158M ▲ $-24K ▼ $28.614M ▲ $13.164M ▲ $-18.182M ▲
Q1-2025 $-30.597M ▼ $-26.149M ▼ $0 ▼ $8.134M ▲ $-16.738M ▼ $-26.149M ▼
Q4-2024 $-23.396M ▼ $-3.351M ▼ $1.324M ▲ $6.991M ▲ $2.717M ▼ $-3.503M ▼
Q3-2024 $10.672M $11.759M $233K $-203K $12.915M $11.644M

Revenue by Products

Product Q3-2024Q1-2025Q2-2025Q3-2025
Reportable Segment
Reportable Segment
 $0 ▲$0 ▲$0 ▲$0 ▲
License
License
 $50.00M ▲$10.00M ▼$20.00M ▲$0 ▼
Service
Service
 $0 ▲$0 ▲$0 ▲$0 ▲

Five-Year Company Overview

Income Statement

Income Statement Sangamo’s income statement reflects a classic clinical‑stage biotech profile: very modest revenue, mostly from collaborations, and no recurring product sales yet. Operating costs, especially research and development and general overhead, are much larger than revenue, so the company has reported meaningful losses every year. Those losses have tended to deepen over time, and earnings per share have stayed clearly negative, showing that the business is still firmly in the investment phase rather than in a sustainable, profit‑generating phase.

Balance Sheet

Balance Sheet The balance sheet has noticeably shrunk over the past several years. Total assets and shareholders’ equity have both come down, which suggests that ongoing losses and spending have eaten into the company’s financial cushion. Cash has declined from earlier levels, while debt exists but is not the dominant item on the balance sheet. Overall, Sangamo now operates with a much thinner capital base than in the past, leaving less room to absorb setbacks without new funding.

Cash Flow

Cash Flow Cash flow data show persistent cash burn from running the business, with operating cash flow negative in most recent years. Free cash flow is also clearly negative, meaning the company spends more cash than it brings in, even after relatively modest investment in equipment and facilities. The one earlier year of positive cash flow looks more like an exception tied to specific events than an ongoing pattern. Going forward, the ability to keep funding operations will likely depend on external capital, new partnerships, or milestone payments rather than internally generated cash.

Competitive Edge

Competitive Edge Sangamo has a distinctive competitive angle through its zinc finger technology, supported by a long history in the field, a large patent portfolio, and know‑how that is difficult to replicate quickly. Strategic partnerships with big pharma players provide external validation and can extend its reach. However, it competes in an intensely crowded gene‑editing and gene‑therapy landscape that includes larger, better‑funded companies using CRISPR and other platforms. Sangamo’s smaller scale and weaker financial position make it more dependent on successful partnerships and positive clinical results to maintain its place in this space.

Innovation and R&D

Innovation and R&D The company’s core strength lies in innovation: its zinc finger platform enables gene editing, gene regulation, cell therapy, and gene therapy from a single underlying technology base. Sangamo has spent heavily on research and development, building a pipeline that includes a late‑stage Fabry disease program and earlier‑stage neurology candidates for pain and rare brain disorders, plus work on advanced viral delivery systems. This focus gives it multiple scientific shots on goal, but also concentrates risk in a small number of key programs that must clear clinical and regulatory hurdles. The overall picture is a highly innovative R&D engine paired with significant scientific and execution uncertainty.

Summary

Sangamo Therapeutics today looks like a high‑science, high‑uncertainty biotech: strong on technology and ideas, but weak on current revenues and profits. Financial statements highlight ongoing losses, shrinking assets, and consistent cash burn, which together point to a need for additional funding over time. On the other hand, the company holds a long‑built zinc finger platform, meaningful intellectual property, and collaborations with major partners, all aimed at diseases with substantial unmet need. The next few years—especially the progress of its Fabry disease program and neurology pipeline—appear critical in determining whether its scientific platform can be converted into a more durable and financially stable business model.

NEWS

November 21, 2025 · 8:05 AM UTC

Sangamo Therapeutics Announces FDA Acceptance of BLA Rolling Submission Request for ST-920 in Fabry Disease

Read more

November 6, 2025 · 8:01 AM UTC

Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2025 Financial Results

Read more

October 30, 2025 · 4:01 PM UTC

Sangamo Therapeutics Announces Third Quarter 2025 Earnings Call

Read more

September 4, 2025 · 8:05 AM UTC

Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at International Congress of Inborn Errors of Metabolism 2025

Read more